SEC Form 4 · accession 0001354488-16-008600
TENAX THERAPEUTICS, INC. · TENX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald T Proehl
Director
Period of report
Nov 22, 2016
Accepted (ET)
Nov 29, 2016 · 3:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000034956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 22, 2016 | P | 15,433 | $1.59 | A | 15,433 | D | |
| Common StockF2 | Nov 23, 2016 | P | 14,449 | $1.76 | A | 29,882 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.65. The reporting person undertakes to provide to Tenax Therapeutics, Inc. (the "Company"), any security holder of the Company, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.73 to $1.79.